Single Amino Acid Modification of Adeno-Associated Virus Capsid Changes Transduction and Humoral Immune Profiles
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vectors have the potential to promote long-term gene expression. Unfortunately, humoral immunity restricts patient treatment and in addition provides an obstacle to the potential option of vector readministration. In this study, we describe a comprehensive characterization of the neutralizing antibody (NAb) response to AAV type 1 (AAV1) through AAV5 both in vitro and in vivo. These results demonstrated that NAbs generated from one AAV type are unable to neutralize the transduction of other types. We extended this observation by demonstrating that a rationally engineered, muscle-tropic AAV2 mutant containing 5 amino acid substitutions from AAV1 displayed a NAb profile different from those of parental AAV2 and AAV1. Here we found that a single insertion of Thr from AAV1 into AAV2 capsid at residue 265 preserved high muscle transduction, while also changing the immune profile. To better understand the role of Thr insertion at position 265, we replaced all 20 amino acids and evaluated both muscle transduction and the NAb response. Of these variants, 8 mutants induced higher muscle transduction than AAV2. Additionally, three classes of capsid NAb immune profile were defined based on the ability to inhibit transduction from AAV2 or mutants. While no relationship was found between transduction, amino acid properties, and NAb titer or its cross-reactivity, these studies map a critical capsid motif involved in all steps of AAV infectivity. Our results suggest that AAV types can be utilized not only as templates to generate mutants with enhanced transduction efficiency but also as substrates for repeat administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Capsid engineering for capsids with resistance to antibodies can be performed through rational design (82 -88).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 3×
“These results suggest that preexisting NAbs in the human population can attenuate vector transduction efficiency and inhibit transgene expression upon systemic application (44).”
BackgroundSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Adeno-associated virus (AAV) vectors have been safely and successfully used in phase I clinical trials (39, 40, 54).”
MethodAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
CD40 AND CD154 IN CELL-MEDIATED IMMUNITY
Grewal, I. S., & Flavell, R. A. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.111 · Cited by 1,539 · cited 1×
“Activated T cells then regulate B cell proliferation, production of immunoglobulins (Ig), Ig class switching, rescue of B lymphocytes from apoptotic death, germinal center formation, and generation of B lymphocyte memory (25).”
BackgroundNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 3×
“In vitro NAb assays, including those performed in this study, have demonstrated a lack of cross-reactivity between different types (22, 23, 26).”
BackgroundXiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Self-citationClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 3×
“In vitro NAb assays, including those performed in this study, have demonstrated a lack of cross-reactivity between different types (22, 23, 26).”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 6×
“In the general human population, over 95% of individuals have been infected by AAV2, with 50% of them having NAbs (3, 4, 6, 10, 18, 21, 24, 27, 35, 48, 62, 65).”
BackgroundResultInfluentialXiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Self-citationMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 1×
“Adeno-associated virus (AAV) vectors have been safely and successfully used in phase I clinical trials (39, 40, 54).”
MethodWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 4×
“A number of surveys have demonstrated that NAb cross-activity exists among types of AAV (6, 10, 27, 45).”
BackgroundInfluentialRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762 · cited 2×
“structs were generated in the pXR2 backbone (57).”
MethodSelf-citationAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Immune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684 · cited 2×
“Different studies suggest that specific antibodies against AAV2 can be found in 30 to 96% of individuals, with 30 to 70% containing NAbs against AAV2 (3, 4, 18, 21, 24, 27, 48, 65).”
BackgroundDystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 2×
“A number of surveys have demonstrated that NAb cross-activity exists among types of AAV (6, 10, 27, 45).”
BackgroundSelf-citationGene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 7×
“Although 11 additional types of AAV have been isolated for gene therapy purposes, little to no cross-reactivity of NAbs is demonstrated among these types in animals (27, 30, 38, 60, 65).”
BackgroundMethodInfluentialDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 3×
“The second approach is to use error-prone PCR to generate a library of AAV variants and select for NAb escape mutants in the presence of NAb in vitro (31, 41, 56).”
BackgroundMethodRutledge, E. A., Halbert, C. L., & Russell, D. W. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.309-319.1998 · Cited by 452 · cited 4×
“AAV1 and -6 share 99% amino acid identity in the capsid, with only 6 amino acid differences (61, 65).”
BackgroundInfluentialNathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421 · cited 1×
“The evidence includes the following: (i) no NAb was detected after muscular injection, and AAV vector transgene expression was observed following readministration of AAV2 vector via muscular injection in MHC class II-deficient mice (42); (ii) transient immunosuppression with CD4 antibody treatment at the time of prima…”
ResultPhase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400 · cited 5×
“5 in sera from AAV2-immunized mice was 5-fold lower than that against AAV2 (7).”
BackgroundSelf-citationMoss, R. B., Rodman, D., Spencer, L. T., Aitken, M. L., Zeitlin, P. L., Waltz, D., Milla, C., Brody, A. S., Clancy, J. P., Ramsey, B., et al. (2004) · Chest · doi:10.1378/chest.125.2.509 · Cited by 390
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366
Self-citationAdeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345 · cited 1×
“The prevalence of NAb in children is lower, ranging from 13 to 25% (9, 35).”
BackgroundUpdate on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)
Erles, K., Seb�kov�, P., & Schlehofer, J. R. (1999) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(199911)59:3<406::aid-jmv22>3.0.co;2-n · Cited by 342 · cited 2×
“Different studies suggest that specific antibodies against AAV2 can be found in 30 to 96% of individuals, with 30 to 70% containing NAbs against AAV2 (3, 4, 18, 21, 24, 27, 48, 65).”
BackgroundCloning and Characterization of Adeno-Associated Virus Type 5
Chiorini, J. A., Kim, F., Yang, L., & Kotin, R. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.2.1309-1319.1999 · Cited by 332 · cited 1×
“To date, 12 types and several variants of AAV have been isolated and sequenced (15, 16, 22, 23, 47, 50, 61, 65).”
BackgroundBrantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327
Mond, J. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80109-x · Cited by 288 · cited 2×
“types mount a T cell-dependent B cell response (46).”
BackgroundRivera, V. M., Gao, G.-P., Grant, R. L., Schnell, M. A., Zoltick, P. W., Rozamus, L. W., Clackson, T., & Wilson, J. M. (2005) · Blood · doi:10.1182/blood-2004-06-2501 · Cited by 276 · cited 2×
“Is there a need for repeat administration of AAV2 vectors? AAV2 vectors induce long-term transgene expression in mice, dogs, and primates (1, 17, 59, 67).”
BackgroundNathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y. C., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2007) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 272 · cited 1×
“The evidence includes the following: (i) no NAb was detected after muscular injection, and AAV vector transgene expression was observed following readministration of AAV2 vector via muscular injection in MHC class II-deficient mice (42); (ii) transient immunosuppression with CD4 antibody treatment at the time of prima…”
ResultScallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271 · cited 1×
“In the general human population, over 95% of individuals have been infected by AAV2, with 50% of them having NAbs (3, 4, 6, 10, 18, 21, 24, 27, 35, 48, 62, 65).”
BackgroundAsokan, A., Conway, J. C., Phillips, J. L., Li, C., Hegge, J., Sinnott, R., Yadav, S., DiPrimio, N., Nam, H.-J., Agbandje-McKenna, M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1599 · Cited by 266 · cited 2×
“To overcome this concern, several approaches have been exploited in our lab and by other groups, including (i) the utilization of polymers to cover the AAV capsid and block NAb recognition (11, 32, 33), (ii) the development of NAb escape mutants by error-prone PCR in vitro (31, 41, 56), (iii) the application of other…”
BackgroundMethodSelf-citationWagner, J. A., Nepomuceno, I. B., Messner, A. H., Moran, M. L., Batson, E. P., Dimiceli, S., Brown, B. W., Desch, J. K., Norbash, A. M., Conrad, C. K., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128577 · Cited by 266
Li, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J. S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Eugene Redmond Jr, D., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.100 · Cited by 261 · cited 2×
“To overcome this concern, several approaches have been exploited in our lab and by other groups, including (i) the utilization of polymers to cover the AAV capsid and block NAb recognition (11, 32, 33), (ii) the development of NAb escape mutants by error-prone PCR in vitro (31, 41, 56), (iii) the application of other…”
BackgroundMethodSelf-citationHalbert, C. L., Rutledge, E. A., Allen, J. M., Russell, D. W., & Miller, A. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.3.1524-1532.2000 · Cited by 259 · cited 9×
“Although 11 additional types of AAV have been isolated for gene therapy purposes, little to no cross-reactivity of NAbs is demonstrated among these types in animals (27, 30, 38, 60, 65).”
BackgroundMethodInfluentialMoskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., & Patel, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1761-1766.2000 · Cited by 253
Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6
Blankinship, M. J., Gregorevic, P., Allen, J. M., Harper, S. Q., Harper, H., Halbert, C. L., Miller, D. A., & Chamberlain, J. S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.016 · Cited by 251 · cited 1×
“AAV1 and AAV6 are known to transduce muscle at a very high efficiency compared to other AAV types (5, 12, 13, 22).”
BackgroundMori, S., Wang, L., Takeuchi, T., & Kanda, T. (2004) · Virology · doi:10.1016/j.virol.2004.10.012 · Cited by 245 · cited 1×
“To date, 12 types and several variants of AAV have been isolated and sequenced (15, 16, 22, 23, 47, 50, 61, 65).”
BackgroundCloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles
Chiorini, J. A., Yang, L., Liu, Y., Safer, B., & Kotin, R. M. (1997) · Journal of Virology · doi:10.1128/jvi.71.9.6823-6833.1997 · Cited by 231 · cited 1×
“To date, 12 types and several variants of AAV have been isolated and sequenced (15, 16, 22, 23, 47, 50, 61, 65).”
BackgroundLi, C., Narkbunnam, N., Samulski, R. J., Asokan, A., Hu, G., Jacobson, L. J., Manco-Johnson, M. J., Monahan, P. E., & The Joint Outcome Study Investigators (2012) · Gene Therapy · doi:10.1038/gt.2011.90 · Cited by 225 · cited 2×
“The prevalence of NAb in children is lower, ranging from 13 to 25% (9, 35).”
BackgroundSelf-citationPeden, C. S., Burger, C., Muzyczka, N., & Mandel, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6344-6359.2004 · Cited by 222 · cited 2×
“The utilization of other types of AAV vectors to overcome AAV2 NAb activity has been performed in several animal models (27, 55, 64).”
BackgroundMethodPreclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy
Grimm, D., Zhou, S., Nakai, H., Thomas, C. E., Storm, T. A., Fuess, S., Matsushita, T., Allen, J., Surosky, R., Lochrie, M., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0495 · Cited by 208 · cited 1×
“In vitro NAb assays, including those performed in this study, have demonstrated a lack of cross-reactivity between different types (22, 23, 26).”
BackgroundHybrid Vectors Based on Adeno-Associated Virus Serotypes 2 and 5 for Muscle-Directed Gene Transfer
Hildinger, M., Auricchio, A., Gao, G., Wang, L., Chirmule, N., & Wilson, J. M. (2001) · Journal of Virology · doi:10.1128/jvi.75.13.6199-6203.2001 · Cited by 207 · cited 3×
“To overcome this concern, several approaches have been exploited in our lab and by other groups, including (i) the utilization of polymers to cover the AAV capsid and block NAb recognition (11, 32, 33), (ii) the development of NAb escape mutants by error-prone PCR in vitro (31, 41, 56), (iii) the application of other…”
BackgroundMethodHalbert, C. L., Standaert, T. A., Aitken, M. L., Alexander, I. E., Russell, D. W., & Miller, A. D. (1997) · Journal of Virology · doi:10.1128/jvi.71.8.5932-5941.1997 · Cited by 205 · cited 1×
“Accordingly, several studies have shown that the presence of NAbs may prevent repeat administration of the same vector (28, 29, 42, 44, 48, 55, 67).”
BackgroundHalbert, C. L., Standaert, T. A., Wilson, C. B., & Miller, A. D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9795-9805.1998 · Cited by 203 · cited 2×
“It is tempting to speculate that blocking T-B cell interactions might represent an effective approach to overcome AAV NAb activity and allow repeat administration (1, 19, 29, 42).”
BackgroundLochrie, M. A., Tatsuno, G. P., Christie, B., McDonnell, J. W., Zhou, S., Surosky, R., Pierce, G. F., & Colosi, P. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.821-834.2006 · Cited by 201 · cited 2×
“To overcome this concern, several approaches have been exploited in our lab and by other groups, including (i) the utilization of polymers to cover the AAV capsid and block NAb recognition (11, 32, 33), (ii) the development of NAb escape mutants by error-prone PCR in vitro (31, 41, 56), (iii) the application of other…”
BackgroundMethodChirmule, N., Xiao, W., Truneh, A., Schnell, M. A., Hughes, J. V., Zoltick, P., & Wilson, J. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.5.2420-2425.2000 · Cited by 198 · cited 2×
“It is tempting to speculate that blocking T-B cell interactions might represent an effective approach to overcome AAV NAb activity and allow repeat administration (1, 19, 29, 42).”
BackgroundResultAnalysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus
Georg-Fries, B., Biederlack, S., Wolf, J., & Zur Hausen, H. (1984) · Virology · doi:10.1016/0042-6822(84)90272-1 · Cited by 195 · cited 2×
“Different studies suggest that specific antibodies against AAV2 can be found in 30 to 96% of individuals, with 30 to 70% containing NAbs against AAV2 (3, 4, 18, 21, 24, 27, 48, 65).”
BackgroundRivière, C., Danos, O., & Douar, A. M. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302766 · Cited by 192 · cited 3×
“To overcome this concern, several approaches have been exploited in our lab and by other groups, including (i) the utilization of polymers to cover the AAV capsid and block NAb recognition (11, 32, 33), (ii) the development of NAb escape mutants by error-prone PCR in vitro (31, 41, 56), (iii) the application of other…”
BackgroundMethodEPIDEMIOLOGY OF ADENOVIRUS-ASSOCIATED VIRUS INFECTION IN A NURSERY POPULATION1
BLACKLOW, N. R., HOGGAN, M. D., KAPIKIAN, A. Z., AUSTIN, J. B., & ROWE, W. P. (1968) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120897 · Cited by 181 · cited 2×
“Different studies suggest that specific antibodies against AAV2 can be found in 30 to 96% of individuals, with 30 to 70% containing NAbs against AAV2 (3, 4, 18, 21, 24, 27, 48, 65).”
BackgroundWang, L., Calcedo, R., Nichols, T. C., Bellinger, D. A., Dillow, A., Verma, I. M., & Wilson, J. M. (2005) · Blood · doi:10.1182/blood-2004-10-3867 · Cited by 173 · cited 1×
“The utilization of other types of AAV vectors to overcome AAV2 NAb activity has been performed in several animal models (27, 55, 64).”
MethodPEG conjugation moderately protects adeno‐associated viral vectors against antibody neutralization
Lee, G. K., Maheshri, N., Kaspar, B., & Schaffer, D. V. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20562 · Cited by 169 · cited 2×
“One of them is to use a polymer to cover the AAV surface and block NAb recognition (11, 32, 33).”
BackgroundMethodSerologic Evidence for Human Infection With Adenovirus-Associated Viruses
(1968) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/40.2.319 · Cited by 166 · cited 2×
“Different studies suggest that specific antibodies against AAV2 can be found in 30 to 96% of individuals, with 30 to 70% containing NAbs against AAV2 (3, 4, 18, 21, 24, 27, 48, 65).”
BackgroundVirally induced modulation of murine IgG antibody subclasses.
Coutelier, J. P., van der Logt, J. T., Heessen, F. W., Vink, A., & van Snick, J. (1988) · The Journal of experimental medicine · doi:10.1084/jem.168.6.2373 · Cited by 160
Nucleotide Sequencing and Generation of an Infectious Clone of Adeno-Associated Virus 3
Muramatsu, S.-I., Mizukami, H., Young, N. S., & Brown, K. E. (1996) · Virology · doi:10.1006/viro.1996.0367 · Cited by 159 · cited 1×
“To date, 12 types and several variants of AAV have been isolated and sequenced (15, 16, 22, 23, 47, 50, 61, 65).”
BackgroundArruda, V. R., Stedman, H. H., Nichols, T. C., Haskins, M. E., Nicholson, M., Herzog, R. W., Couto, L. B., & High, K. A. (2005) · Blood · doi:10.1182/blood-2004-07-2908 · Cited by 153 · cited 3×
“It is tempting to speculate that blocking T-B cell interactions might represent an effective approach to overcome AAV NAb activity and allow repeat administration (1, 19, 29, 42).”
BackgroundManning, W. C., Zhou, S., Bland, M. P., Escobedo, J. A., & Dwarki, V. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.4-477 · Cited by 140 · cited 3×
“It is tempting to speculate that blocking T-B cell interactions might represent an effective approach to overcome AAV NAb activity and allow repeat administration (1, 19, 29, 42).”
BackgroundResultCombinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus
Perabo, L., Endell, J., King, S., Lux, K., Goldnau, D., Hallek, M., & Büning, H. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.849 · Cited by 136 · cited 2×
“The second approach is to use error-prone PCR to generate a library of AAV variants and select for NAb escape mutants in the presence of NAb in vitro (31, 41, 56).”
MethodHuttner, N. A., Girod, A., Perabo, L., Edbauer, D., Kleinschmidt, J. A., Büning, H., & Hallek, M. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302123 · Cited by 124 · cited 2×
“The second approach is to use error-prone PCR to generate a library of AAV variants and select for NAb escape mutants in the presence of NAb in vitro (31, 41, 56).”
MethodChao, H., Monahan, P. E., Liu, Y., Samulski, R. J., & Walsh, C. E. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0449 · Cited by 115 · cited 1×
“AAV1 and AAV6 are known to transduce muscle at a very high efficiency compared to other AAV types (5, 12, 13, 22).”
BackgroundSelf-citationXiao, W., Chirmule, N., Schnell, M. A., Tazelaar, J., Hughes, J. V., & Wilson, J. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0045 · Cited by 114
Pneumococcal polysaccharides induce antibody formation by human B lymphocytes in vitro.
Rijkers, G. T., & Mosier, D. E. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.1.1 · Cited by 109 · cited 1×
“, bacterial capsular polysaccharides) (58).”
Persistent expression of canine factor IX in hemophilia B canines
Chao, H., Samulski, R. J., Bellinger, D. A., Monahan, P. E., Nichols, T. C., & Walsh, C. E. (1999) · Gene Therapy · doi:10.1038/sj.gt.3301024 · Cited by 106
Self-citationDiverse IgG subclass responses to adeno‐associated virus infection and vector administration
Murphy, S. L., Li, H., Mingozzi, F., Sabatino, D. E., Hui, D. J., Edmonson, S. A., & High, K. A. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21360 · Cited by 101 · cited 2×
“The evidence includes the following: (i) no NAb was detected after muscular injection, and AAV vector transgene expression was observed following readministration of AAV2 vector via muscular injection in MHC class II-deficient mice (42); (ii) transient immunosuppression with CD4 antibody treatment at the time of prima…”
ResultLi, C., Hirsch, M., Asokan, A., Zeithaml, B., Ma, H., Kafri, T., & Samulski, R. J. (2007) · Journal of Virology · doi:10.1128/jvi.00529-07 · Cited by 87 · cited 1×
“The evidence includes the following: (i) no NAb was detected after muscular injection, and AAV vector transgene expression was observed following readministration of AAV2 vector via muscular injection in MHC class II-deficient mice (42); (ii) transient immunosuppression with CD4 antibody treatment at the time of prima…”
ResultSelf-citationUtility of PEGylated recombinant adeno-associated viruses for gene transfer
Le, H. T., Yu, Q.-C., Wilson, J. M., & Croyle, M. A. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.07.019 · Cited by 82 · cited 2×
“One of them is to use a polymer to cover the AAV surface and block NAb recognition (11, 32, 33).”
BackgroundMethodCarlisle, R. C., Benjamin, R., Briggs, S. S., Sumner‐Jones, S., McIntosh, J., Gill, D., Hyde, S., Nathwani, A., Subr, V., Ulbrich, K., et al. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1161 · Cited by 61
Chiorini, J. A., Yang, L., Safer, B., & Kotin, R. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.11.7334-7338.1995 · Cited by 57 · cited 1×
“Is there a need for repeat administration of AAV2 vectors? AAV2 vectors induce long-term transgene expression in mice, dogs, and primates (1, 17, 59, 67).”
BackgroundOptimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes
Maersch, S., Huber, A., Büning, H., Hallek, M., & Perabo, L. (2010) · Virology · doi:10.1016/j.virol.2009.10.021 · Cited by 50 · cited 3×
“To overcome this concern, several approaches have been exploited in our lab and by other groups, including (i) the utilization of polymers to cover the AAV capsid and block NAb recognition (11, 32, 33), (ii) the development of NAb escape mutants by error-prone PCR in vitro (31, 41, 56), (iii) the application of other…”
BackgroundMethodGenetic analysis of the antibody response to AAV2 and factor IX
Zhang, H., High, K. A., Wu, Q., Yang, P., Schlachterman, A., Yu, S., Yi, N., Hsu, H., & Mountz, J. D. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.02.014 · Cited by 15 · cited 1×
“The evidence includes the following: (i) no NAb was detected after muscular injection, and AAV vector transgene expression was observed following readministration of AAV2 vector via muscular injection in MHC class II-deficient mice (42); (ii) transient immunosuppression with CD4 antibody treatment at the time of prima…”
Result
Cited by
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Self-citationAAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Self-citationHastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
“Further, single amino acid changes in the capsid proteins result in vectors with less immunogenicity and improved transduction.(86) Limitations to vector packaging size also continue to be explored and may soon result in generation of vectors with room for larger transgene inserts.”
Self-citationPromoterless gene targeting without nucleases ameliorates haemophilia B in mice
Barzel, A., Paulk, N. K., Shi, Y., Huang, Y., Chu, K., Zhang, F., Valdmanis, P. N., Spector, L. P., Porteus, M. H., Gaensler, K. M., et al. (2015) · Nature · doi:10.1038/nature13864 · Cited by 257
Metadata
- Authors
- Li, C., Diprimio, N., Bowles, D. E., Hirsch, M. L., Monahan, P. E., Asokan, A., Rabinowitz, J., Agbandje-McKenna, M., & Samulski, R. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Department of Biochemistry and Molecular Biology, Center for Structural Biology, The McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2012-08
- Volume
- 86
- Issue
- 15
- Pages
- 7752-7759
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC3421647
- OpenAlex
- W2107586018
- Cited by
- 96
- References
- 69
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 10 · 2021: 7 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 9 · 2016: 8 · 2015: 10 · 2014: 10 · 2013: 9
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (5u54ar056953-05)
- National Heart, Lung, and Blood Institute (P01HL059412, R01HL089221)
- National Institute of General Medical Sciences (R01GM082946)
- National Institute of Allergy and Infectious Diseases (R01AI072176, R01AI080726, AI072176)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK084033, DK084033)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54-AR056953)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- adeno-associated virus, AAV capsid, amino acid substitutions, neutralizing antibodies, humoral immunity, AAV1, AAV2, AAV5, capsid engineering, cross-reactivity, gene therapy vectors
- MeSH terms
- Dependovirus, Animals, Antibodies, Viral, Capsid, Cell Line, Chlorocebus aethiops, Female, Humans, Male, Mice, Inbred BALB C, Transduction, Genetic, Muscle, Skeletal, COS Cells, Amino Acid Substitution, Mice, Immunity, Humoral, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.